Use of maternal plasma for noninvasive determination of fetal RhD status - 25/08/11
, Kirstin M. Finning, PhD b, Pete Martin b, Kenneth J. Moise, MD a
Reprint requests: Terry C. Harper, MD, CB #7516 MacNider Building, 101 Manning Drive, Chapel Hill, NC 27599.Résumé |
Determination of the fetal RhD typing using free fetal DNA in maternal plasma is beginning to enjoy widespread acceptance in Europe. Case 1, the partner of an RhD-sensitized patient, was identified with a heterozygous paternal phenotype by serologic testing. Maternal plasma was drawn at 18 weeks' gestation to determine the fetal RhD status. The result was unable to be reported as RhD negative; the patient subsequently underwent amniocentesis to confirm an RhD-negative fetus. Case 2, a partner of another RhD-sensitized patient, was similarly identified with a heterozygous paternal phenotype by serologic testing. Maternal plasma was also drawn at 18 weeks' gestation to determine the fetal RhD status. It returned RhD negative and allowed for the avoidance of invasive testing for the remainder of the pregnancy. Therefore, maternal plasma testing for fetal RhD status represents a new tool in the management of the cases of RhD alloimmunization in pregnancy.
Le texte complet de cet article est disponible en PDF.Key words : Alloimmunization, RhD, Maternal plasma, Hemolytic disease of the fetus/newborn
Plan
Vol 191 - N° 5
P. 1730-1732 - novembre 2004 Retour au numéro
Article précédent
- Hypogonadotropic hypogonadism in a female with the Johnson-McMillin syndrome
- Fleur De Metsenaere, Geert Mortier, Marc Dhont
- Leiomyosarcoma in a premenopausal patient after uterine artery embolization
- Jay Goldberg, Irina Burd, Fredric V. Price, Robert Worthington-Kirsch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?